New Treatment Paradigms in the Management of Metastatic Bladder Cancer: A Closer Look at Emerging Therapies Following Immunotherapy Failure

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from July 1, 2020 to August 1, 2021

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by an educational grant from
Astellas and Seattle Genetics

Bladder cancer, also known as urothelial carcinoma, is the ninth leading cause of cancer death in the United States. According to the American Cancer Society, there will be 80,470 new cases of bladder cancer in 2020. Before the advent of new treatments in recent years, the basic management of this illness has remained unchanged for decades. Long-term survival for people diagnosed with advanced bladder cancer is poor, with approximately 5% of patients with metastatic bladder cancer surviving for 5 years or more. As the role of the immune system in oncogenesis and therapy has become clearer across cancer types, new approaches emerged with important benefits in metastatic bladder cancer, which led to the introduction of immune checkpoint inhibitors. However, when those options fail, options are sparse to manage this difficult disease. Fortunately for patients with metastatic bladder cancer, new agents, including antibody-drug conjugates, have recently emerged for patients who have failed on immunotherapy and chemotherapy. While immunotherapy has revolutionized care for metastatic bladder cancer, it doesn't work for everyone. Patients who progress with or fail immunotherapy will need subsequent therapy, and there is limited data to guide treatment selection. New data from late-stage clinical trials introduce emerging targeted agents with great promise in improving outcomes for these patients.

Upon completion of this activity, participants will be able to:

  • Examine challenges and barriers to treatment and management of patients with metastatic bladder cancer following immune checkpoint inhibitors

  • Analyze recent efficacy and safety data on emerging therapies for the treatment of metastatic bladder cancer following immunotherapy failure

  • Explore the emerging role of antibody-drug conjugates in the management of metastatic bladder cancer

  • Assess strategies for anticipating, recognizing, and managing adverse events of emerging targeted therapies in patients with metastatic bladder cancer

  • Integrate managed care considerations for novel agents based on efficacy and safety data and the value of biomarkers in therapeutic decision-making


Faculty: Peter H. O’Donnell, MD
Associate Professor
Department of Medicine
Genitourinary Oncology Program
The University of Chicago


Dr. O'Donnell serves on an advisory board for Merck. He has received honoraria from Antheneum Partners, Astellas, Dedham group, FirstWord Publication, Genentech/Roche, Health Advances, Janssen, Merk, OncLive, Seattle Genetics, and Schlesinger Associates. He has received grant/research support from Acerta Pharma, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech/Roche, Janssen, Merck, and Seattle Genetics. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by an educational grant from
Astellas and Seattle Genetics

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue